Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.
about
Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer's Disease.Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer's disease-like pathologies.Telmisartan Activates PPARδ to Improve Symptoms of Unpredictable Chronic Mild Stress-Induced Depression in Mice.Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease.The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at 'Type 3 Diabetes', Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments.
P2860
Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting Alzheimer's Disease ...... Reverses Disease Pathologies.
@en
Targeting Alzheimer's Disease ...... ecule Nuclear Receptor Agonist
@nl
type
label
Targeting Alzheimer's Disease ...... Reverses Disease Pathologies.
@en
Targeting Alzheimer's Disease ...... ecule Nuclear Receptor Agonist
@nl
prefLabel
Targeting Alzheimer's Disease ...... Reverses Disease Pathologies.
@en
Targeting Alzheimer's Disease ...... ecule Nuclear Receptor Agonist
@nl
P2093
P2860
P1476
Targeting Alzheimer's Disease ...... Reverses Disease Pathologies.
@en
P2093
Cesar Dominguez
John Didsbury
Suzanne M de la Monte
P2860
P356
10.4172/2161-0460.1000238
P577
2016-06-03T00:00:00Z